The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Abstract
BACKGROUND: The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. METHODS: We conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients with advanced, well-differentiated pancreatic neuroendocrine tumors. All patients had Response Evaluation Criteria in Solid Tumors-defined disease progression documented within 12 months before baseline. A total of 171 patients were randomly assigned (in a 1:1 ratio) to receive best supportive care with either sunitinib at a dose of 37.5 mg per day or placebo. The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety. RESULTS: The study was discontinued early, after the independent data and safety monitoring committee observed more serious adverse events and deaths in the placebo group as well as a difference in progression-free survival favoring sunitinib. Median progression-free survival was 11.4 months in the sunitinib group as compared with 5.5 months in the placebo group (hazard ratio for progression or death, 0.42; 95% confidence interval [CI], 0.26 to 0.66; P<0.001). A Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied. The objective response rate was 9.3% in the sunitinib group versus 0% in the placebo group. At the data cutoff point, 9 deaths were reported in the sunitinib group (10%) versus 21 deaths in the placebo group (25%) (hazard ratio for death, 0.41; 95% CI, 0.19 to 0.89; P=0.02). The most frequent adverse events in the sunitinib group were diarrhea, nausea, vomiting, asthenia, and fatigue. CONCLUSIONS: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00428597.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Self-citationMoertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Self-citationMicroenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,292
Self-citationPavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 972
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Self-citationPavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationAntiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Self-citationCheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Self-citationNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv041 · Cited by 714
Self-citationTabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 614
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., Chen, H., Jensen, R. T., Kim, M. K., Klimstra, D. S., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828e34a4 · Cited by 580
Annual report to the nation on the status of cancer, part 1: National cancer statistics
Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., et al. (2022) · Cancer · doi:10.1002/cncr.34479 · Cited by 557
Tsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Öberg, K., Knigge, U., Kwekkeboom, D., & Perren, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 524
Marinoni, I., Kurrer, A. S., Vassella, E., Dettmer, M., Rudolph, T., Banz, V., Hunger, F., Pasquinelli, S., Speel, E., & Perren, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.020 · Cited by 463
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Ito, T., Igarashi, H., Nakamura, K., Sasano, H., Okusaka, T., Takano, K., Komoto, I., Tanaka, M., Imamura, M., Jensen, R. T., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0934-2 · Cited by 405
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Howe, J. R., Merchant, N. B., Conrad, C., Keutgen, X. M., Hallet, J., Drebin, J. A., Minter, R. M., Lairmore, T. C., Tseng, J. F., Zeh, H. J., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001454 · Cited by 396
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Neuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J., Jansen, G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1667 · Cited by 345
Hicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 336
Self-citationPreclinical mouse solid tumour models: status quo, challenges and perspectives
Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
Provenzano, P. P., & Hingorani, S. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.569 · Cited by 323
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Angiogenesis in pancreatic cancer: current research status and clinical implications
Li, S., Xu, H.-X., Wu, C.-T., Wang, W.-Q., Jin, W., Gao, H.-L., Li, H., Zhang, S.-R., Xu, J.-Z., Qi, Z.-H., et al. (2019) · Angiogenesis · doi:10.1007/s10456-018-9645-2 · Cited by 284
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
de Baere, T., Arai, Y., Lencioni, R., Geschwind, J.-F., Rilling, W., Salem, R., Matsui, O., & Soulen, M. C. (2016) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-015-1208-y · Cited by 272
Kos‐Kudła, B., Castaño, J. P., Denecke, T., Grande, E., Kjaer, A., Koumarianou, A., de Mestier, L., Partelli, S., Perren, A., Stättner, S., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13343 · Cited by 256
Self-citationFine, R. L., Gulati, A. P., Krantz, B. A., Moss, R. A., Schreibman, S., Tsushima, D. A., Mowatt, K. B., Dinnen, R. D., Mao, Y., Stevens, P. D., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2055-z · Cited by 253
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1685381 · Cited by 135
“proven cytostatic activity for pancreatic NETs only [8].”
BackgroundWell-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
de Wilde, R. F., Edil, B. H., Hruban, R. H., & Maitra, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.9 · Cited by 122
Approach to the Patient: Insulinoma
Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad641 · Cited by 91
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/154541 · Cited by 69
“The more the tumor expresses somatostatin receptors as compared to the surrounding tissue, the more effective the PRRT will be.”
BackgroundJeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.06.001 · Cited by 59
Targeted α-emitter therapy of neuroendocrine tumors.
Kunikowska, J., & Królicki, L. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.11.003 · Cited by 52
The treatment of hyperinsulinemic hypoglycaemia in adults: an update
On behalf of NIKE Group, Davi′, M. V., Pia, A., Guarnotta, V., Pizza, G., Colao, A., & Faggiano, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0536-3 · Cited by 51
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Chen, J., Wang, C., Han, J., Luan, Y., Cui, Y., Shen, R., Sha, D., Cong, L., Zhang, Z., & Wang, W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.45 · Cited by 37
Self-citationFriebe, L., Freitag, M. T., Braun, M., Nicolas, G., Bauman, A., Bushnell, D., Christ, E., & Wild, D. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265894 · Cited by 25
Yang, K., Li, J., Cheng, Y., & Bai, C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0441 · Cited by 4
Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jäntti, C., et al. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.941999
Metadata
- Authors
- Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., Chen, J.-S., Hörsch, D., Hammel, P., Wiedenmann, B., Van Cutsem, E., Patyna, S., Lu, D. R., Blanckmeister, C., Chao, R., & Ruszniewski, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-10
- Volume
- 364
- Issue
- 6
- Pages
- 501-513
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158474413
- Cited by
- 2,567
- References
- 35
- FWCI
- 164.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.